Rhapsogen's President and CEO is a seasoned biotechnology executive with more than 30 years of experience spanning drug discovery, development and regulatory approval. Author of over 70 scientific publications and inventor on more than 60 patents, with a proven track record of advancing multiple therapeutics from discovery through FDA approval.  At Rhapsogen he's leading the development of precision biologics for IgG-mediated autoimmune and inflammatory diseases.

‍